🇺🇸 FDA
Pipeline program

CEA-targeted CAR-T (Intravenous)

2025-0883

Phase 1 mab active

Quick answer

CEA-targeted CAR-T (Intravenous) for NSCLC (Advanced Non-small Cell Lung Cancer) is a Phase 1 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials